Cytokine Signalling Forum

Publications





November 21

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials

Winthrop KL, Nash P, Yamaoka K, Mysler E, Khan N, Camp HS, Song Y, Suboticki JL, Curtis JR.
Ann Rheum Dis. 2021. Epub ahead of print. doi: 10.1136/annrheumdis-2021-220822.

JAKinibs have been linked with an increased risk of HZ in patients with RA. To this end, Winthrop, et al. evaluated data from six Phase III clinical trials to determine the incidence of HZ in the upadacitinib (UPA)-treated patients with RA and identify potential risk factors for the development of HZ in these patients. Analysis of data provides further support for the need for continued vigilance and monitoring for signs of herpes zoster (HZ) in patients receiving UPA, particularly in Asian popu...

August 21

Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Rheumatoid Arthritis: Results From SELECT-EARLY and SELECT-MONOTHERAPY

Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M.
Rheumatology (Oxford). 2021;60(7):3209–21

Upadacitinib treatment results in statistically significant and clinically meaningful improvements in health-related quality of life. Strand, et al. evaluated the effect of upadacitinib monotherapy versus methotrexate (MTX) on patient-reported outcomes (PRO) in MTX-naïve and MTX-inadequate responder patients with moderately-to-severely active RA. Their research from the SELECT-EARLY and SELECT-MONOTHERAPY randomised controlled trials found that upadacitinib monotherapy resulted in clinical...

Keywords: JAK, Upadacitinib, Clinical, PRO